NetworkNewsBreaks Archive - Page 2110 of 2180

MondayMar 27, 2017 9:38 am

NetworkNewsBreaks – eXp World Holdings, Inc. (EXPI) Scheduled to Present at The MicroCap Conference on April 4

eXp World Holdings, Inc. (OTCQB: EXPI), holding company for the Agent-Owned Cloud Brokerage®, this morning announced that its management team will be attending The MicroCap Conference in New York on Tuesday, April 4, 2017. The company is scheduled to present at 9:30 a.m. ET at the JW Marriott Essex House New York, which is located adjacent to Central Park in Manhattan. The EXPI team will also host one-on-one meetings with prospective investors throughout the day. A webcast of the company’s presentation will be made available at http://wsw.com/webcast/microcapconf3/expi for those who are unable to attend the event. For more information about…

FridayMar 24, 2017 11:55 am

NetworkNewsBreaks – Top 10 Mid-day Percentage Gainers on March 24, 2017

Here is a list of stocks shaking up the markets today, with particular focus on NASDAQ and OTC small caps. The top gainers based on percentage: ZAIS 47.73% – News: Posts Q4, FY 2016 results LKAI 23.07% – News: Three largest shareholders increased their holdings ADAC 16.00% – News: Secures contracts with two marquis clients EBIO 8.42% – News: Posts Q4, FY 2016 results TLRS 7.66% – News: Increases and extends private placement HDYN 6.21% – News: Reconvening annual stockholders meeting on April 19 ENCR 5.94% – News: Holding a conference call to discuss FY 2016 on April 13 FNJN…

FridayMar 24, 2017 11:27 am

NetworkNewsBreaks – Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) Receives ‘Buy’ Rating, $12 PT

Aegis Capital recently issued a ‘Buy’ rating and price target of $12 on shares of Corbus Pharmaceuticals Holdings (NASDAQ: CRBP). The company’s fourth quarter was marked by positive data from its phase 2 study of anabasum (previously Resunab or JBT-101) for the treatment of systemic sclerosis showing clear signal of clinical benefit. On March 13, Corbus held a Research and Development day and said the anticipated data from the phase 2a study in cystic fibrosis is on schedule for announcement during March 2017. Aegis cited this data as a possible milestone to drive shares of the company’s stock. For more…

FridayMar 24, 2017 11:25 am

NetworkNewsBreaks – R-Three Technologies, Inc. (RRRT) Suspends Operations; Triggers Sell-off

R-Three Technologies (OTC: RRRT) shares are down more than 80% mid-morning after the company announced the temporary suspension of its operations. The suspension is pending funding, in either debt or equity financing, to implement the company's business plan. The business plan is to produce a variety of products, such as interlocking asphalt bricks, using recycled asphalt shingles. "The company is attempting to secure a minimum of $200,000 in debt or equity financing. If we secure such level of funding, the Company will be in a position to continue to lay the foundation to implement our business plan. An additional $800,000…

FridayMar 24, 2017 11:23 am

NetworkNewsBreaks – Aegis Capital Reiterates ‘Buy’ Rating, $11 PT on Conatus Pharmaceuticals Inc. (NASDAQ: CNAT)

Aegis Capital recently reiterated a ‘Buy’ rating and price target of $11 on shares of Conatus Pharmaceuticals (NASDAQ: CNAT). The company’s recent exclusive option, collaboration and license agreement with Novartis (NYSE: NVS) for the global development and commercialization of its lead product emricasan is cited as a positive catalyst by Aegis. For more information, visit www.conatuspharma.com About Conatus Pharmaceuticals Conatus is a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease. Conatus is developing its lead compound, emricasan, for the treatment of patients with chronic liver disease. Emricasan is designed to reduce the activity…

FridayMar 24, 2017 11:21 am

NetworkNewsBreaks – Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) Issued ‘Buy’ Rating, $8 PT at Aegis Capital

Aegis Capital has issued a ‘Buy’ rating and price target of $8 on shares of Ritter Pharmaceuticals (NASDAQ: RTTR). The company recently modified the primary endpoint of its phase 2b/3 clinical trial of RP-G28, following a meeting with the FDA, in hopes of being considered as a pivotal trial, which would shorten the time frame to approval and revenues. The report by Aegis cites the anticipated release of results from the phase 2b/3 clinical trial of RP-G28, which is expected by the end of the month. For more information, visit www.ritterpharma.com About Ritter Pharmaceuticals Ritter Pharmaceuticals, Inc. develops novel therapeutic products…

FridayMar 24, 2017 11:18 am

NetworkNewsBreaks – Xenon Pharmaceuticals, Inc. (NASDAQ: XENE) Shares Dive; XEN801 Disappoints in Phase 2 Clinical Trial

Shares of Xenon Pharmaceuticals (NASDAQ: XENE) are down 51% after the company reported topline efficacy results from the phase 2 clinical trial to evaluate the efficacy, safety, tolerability and systemic exposure of XEN801 for the treatment of moderate to severe facial acne. Trial results show that XEN801 did not demonstrate a statistically significant difference from vehicle placebo in its primary endpoint of the percent change in total lesion count from baseline to week 12. Results also show that XEN801 did not demonstrate statistical significance relative to key secondary efficacy endpoints. “Despite the good scientific and preclinical rationale to pursue SCD1…

FridayMar 24, 2017 11:15 am

NetworkNewsBreaks – Aegis Capital Reiterates ‘Buy’ Rating, $11 PT on ViewRay, Inc. (NASDAQ: VRAY)

Aegis Capital has reiterated its ‘Buy’ rating and price target of $11 on shares of ViewRay, Inc. (NASDAQ: VRAY). The action follows the release of ViewRay’s financial results, including fourth-quarter 2016 revenue of $16.1 million. Operating costs for the quarter were $9.3 million, down from $10.7 million for the fourth quarter of 2015. ViewRay also provided an outlook for 2017, including an update on the MRIdian LINAC system. The company reported a clear increase in interest in the system after receiving FDA approval in February. Orders are anticipated to further increase in 2017, driving revenue for the year. For more…

ThursdayMar 23, 2017 2:52 pm

NetworkNewsBreaks – MGX Minerals, Inc. (MGXMF) Enters Agreement to Acquire Working Interest in Paradox Basin

Diversified mining company MGX Minerals, Inc. (OTC: MGXMF) today announced its entry into a joint operating agreement with a private vendor to act as operator and acquire a 75 percent working interest in certain underlying oil and gas leases located contiguous to MGX’s Lisbon Valley petrolithium project. The agreement calls for payments totaling $2 million due on or before September 1, 2018. An accelerated payment schedule reflecting discounted payments is also outlined in the agreement terms. Per the news release, the related leases cover portions of San Juan County, Utah, and San Miguel County, Colorado, including access to the brine-bearing…

ThursdayMar 23, 2017 1:41 pm

NetworkNewsBreaks – ProBility Media Corp. (PBYA) Reports Record Sales for Fiscal Quarter Ended January 31, 2017

Education technology company ProBility Media Corp. (OTCQB: PBYA) today announced its filing of Form 10-Q for its fiscal first quarter ended January 31, 2017. Notably, the company achieved its third consecutive quarter of year-over-year revenue growth, reporting a 13 percent year-over-year increase to $1 million for the three-month period. “We would like to congratulate and thank the ProBility team for continuing to hit record sales, in addition to many other extraordinary accomplishments achieved over the last year,” Evan Levine, Noah Davis and Steven Plumb, executive management of ProBility Media, noted in a joint statement in the news release. “Through enthusiastic…

Financial news and publishing for public and private companies

Contact us: 512.354.7000

NetworkNewsBreaks